Voyager Therapeutics (VYGR) CFO granted 150,500 options and RSUs

Rhea-AI Filing Summary

Voyager Therapeutics’ Chief Financial Officer Nathan D. Jorgensen reported new equity awards. He received 32,250 shares of common stock for no cash cost, issuable under restricted stock units that vest over three years starting on February 6, 2026, subject to continued service.

He was also granted a stock option to buy 150,500 shares at an exercise price of $3.68 per share. This option vests monthly over four years starting on February 6, 2026. After these grants, he directly beneficially owned 156,084 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jorgensen Nathan D.

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A		32,250(1)	A	$0.00	156,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.68	02/06/2026		A		150,500		(2)	02/06/2036	Common Stock	150,500	$0.00	150,500	D

Explanation of Responses:

1. Consists of shares of common stock issuable under an aggregate of 32,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Nathan D. Jorgensen	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Voyager Therapeutics (VYGR) disclose for its CFO?

Voyager Therapeutics disclosed that CFO Nathan D. Jorgensen received new equity awards. He was granted 32,250 restricted stock units and a stock option for 150,500 shares, reported as acquisitions at no cash price in a Form 4 dated February 6, 2026.

How many stock options did the Voyager Therapeutics (VYGR) CFO receive?

The CFO received a stock option covering 150,500 shares of Voyager Therapeutics common stock. The option carries an exercise price of $3.68 per share and vests over four years in 1/48th monthly installments starting on February 6, 2026, subject to continued service.

What restricted stock units were granted to the Voyager Therapeutics (VYGR) CFO?

He was awarded 32,250 restricted stock units under the 2025 Stock Incentive Plan. Each RSU represents one share of common stock and vests over three years, with one-third vesting each year on anniversaries of the February 6, 2026 grant date, contingent on continued service.

What was the reported ownership of Voyager Therapeutics (VYGR) shares after the CFO’s Form 4 transactions?

Following the reported RSU-related acquisition, Nathan D. Jorgensen beneficially owned 156,084 shares of Voyager Therapeutics common stock directly. This figure reflects his non-derivative holdings after the February 6, 2026 grant reported in the Form 4 filing.

What are the vesting terms for the Voyager Therapeutics (VYGR) CFO’s new stock option?

The option vests over four years, starting on February 6, 2026. One forty-eighth of the 150,500 underlying shares vests on the one-month anniversary of that date, with an additional 1/48th vesting monthly thereafter, provided the CFO continues his service with the company.

Under which plan were the Voyager Therapeutics (VYGR) CFO’s RSUs and options granted?

Both the 32,250 restricted stock units and the 150,500-share stock option were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The plan governs the vesting schedules and links full vesting to the CFO’s ongoing service with the company.